Article
Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
European journal of cancer (Oxford, England : 1990) - 1 Feb 2016
Boer Hink, Westerink Nico-Derk L, Altena Renske, Nuver Janine, Dijck-Brouwer D A Janneke, van Faassen Martijn, Klont Frank, Kema Ido P, Lefrandt Joop D, Zwart Nynke, Boezen H Marike, Smit Andries J, Meijer Coby, Gietema Jourik A
Abstract excerpt
PURPOSE: Chemotherapy-treated testicular cancer survivors are at risk for development of the metabolic syndrome, especially in case of decreased androgen levels. Polymorphisms in the gene encoding steroid 5-α-reductase type II (SRD5A2) are involved in altered androgen metabolism. We investigated whether single-nucleotide polymorphisms (SNPs) rs523349 (V89L) and rs9282858 (A49T) in SRD5A2 are associated with...
Read the complete abstract on PubMed